Table S6. Therapies prior to anticoagulants and therapeutic duration

| Studies | Treatments prior to corresponding anticoagulants | Duration of treatment |
|---|---|---|
| Spiezia 2022 | - | - |
| Wik 2021 | Subcutaneous low molecular weight heparin (LMWH) or intravenous unfractionated heparin. | 5 to 7 days. |
| Sebastian 2018 | Endovascular thrombus removal therapy followed by stent replacement. | - |
| Prandoni 2019 | Unfractionated or LMWH overlapped with and followed by VKA. | - |
| Cheung 2016 | Subcutaneous enoxaparin. | - |
| Jeraj 2017 | Rivaroxaban group: 15 mg rivaroxaban twice daily.<br>Warfarin group: dalteparin in weight-adjusted dose. | Rivaroxaban group: three weeks.<br>Warfarin group: initial 5 to 7 days. |
| Utne 2018 | Initial LMWH and warfarin or rivaroxaban. | - |
| Ferreira 2020 | Warfarin group: enoxaparin | - |
| de Athayde 2019 | Patients were hospitalized and received initial anticoagulation with subcutaneous enoxaparin or intravenous unfractionated heparin. | At least 48 to 72 hours. |
| Norberto 2016 | - | - |
| González-Fajardo 2008 | Twice daily enoxaparin 40 mg. | 1 week. |